Treatment of ECL cell carcinoids with octreotide LAR

Fykse, Vidar; Sandvik, A. K.; Qvigstad, Gunnar; Falkmer, Sture; Syversen, Unni; Waldum, Helge L.

doi:10.1080/00365520410005225

Cited by 69 publications

(51 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As an alternative, SSA therapy has been used. This was associated with regression of these lesions and occasionally reductions in circulating gastrin (Fykse et al 2004, Campana et al 2008, but the effects are short term (w1 year) and disease progression has been noted at 5 years following the termination of therapy (Jianu et al 2011).…”

Section: Typementioning

confidence: 99%

Neuroendocrine tumor disease: an evolving landscape

Frilling

Åkerström

Falconi

et al. 2012

Endocrine-Related Cancer

148

106

View full text Add to dashboard Cite

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) represent a heterogenous group of tumors arising from a variety of neuroendocrine cell types. The incidence and prevalence of GEPNENs have markedly increased over the last three decades. Symptoms are often absent in early disease, or vague and nonspecific even in advanced disease. Delayed diagnosis is thus common. Chromogranin A is the most commonly used biomarker but has limitations as does the proliferative marker Ki-67%, which is often used for tumor grading and determination of therapy. The development of a multidimensional prognostic nomogram may be valuable in predicting tumor behavior and guiding therapy but requires validation. Identification of NENs that express somatostatin receptors (SSTR) allows for SSTR scintigraphy and positron emission tomography imaging using novel radiolabeled compounds. Complete surgical resection of limited disease or endoscopic ablation of small lesions localized in stomach or rectum can provide cure; however, the majority of GEP-NENs are metastatic (most frequently the liver and/or mesenteric lymph nodes) at diagnosis. Selected patients with metastatic disease may benefit from advanced surgical techniques including hepatic resection or liver transplantation. Somatostatin analogs are effective for symptomatic treatment and exhibit some degree of antiproliferative activity in small intestinal NENs. There is a place for streptozotocin, temozolomide, and capecitabine in the management of pancreatic NENs, while new agents targeting either mTOR (everolimus) or angiogenic (sunitinib) pathways have shown efficacy in these lesions.

show abstract

Section: Typementioning

confidence: 99%

Neuroendocrine tumor disease: an evolving landscape

Frilling

Åkerström

Falconi

et al. 2012

Endocrine-Related Cancer

148

106

View full text Add to dashboard Cite

show abstract

“…Therefore, SSAs may suppress tumor growth either directly, through their effect on SSTR expressing cells, or indirectly, via the inhibition of angiogenic factors, such as VEGF [66] . Finally, SSAs have an antisecretive role, as supported by a study by Fykse et al [67] in which five patients with hypergastrinemia and GCs were every month treated with octreotide LAR over one year with the consequent significant reduction in tumor burden, ECL cell grade of hyperplasia and the normalization of circulating chromogranin A levels. A further study [23] reported a significant reduction in gastrin levels and tumor regression in three patients suffering from Zollinger-Ellison syndrome and treated with lanreotide or octreotide for one year.…”

Section: Benefits Of Ssas Therapymentioning

confidence: 78%

Somatostatin analogs for gastric carcinoids: For many, but not all

Massironi

Zilli

Conte

2015

WJG

View full text Add to dashboard Cite

show abstract

“…Antrectomy may be indicated in frequently recurring type 1 tumours 12 , but total gastrectomy should be a rather exceptional indication for this type. Tumoristatic effects of somatostatin analogs have been confirmed by a few small clinical studies [13][14][15][16][17][18] . Somatostatin analog (octreotide) was used in our work with good therapeutical effect in 6 patients with recurring small multiple tumour lesions.…”

Section: Typementioning

confidence: 81%

“…Thus, gastrin suppression and tumoristatic effect may be achieved using somatostatin analogs (octreotide or lanreotide) in recurrent and multiple lesion type 1 NETs or type 2 (ref. [14][15][16][17][18]20 ). Antrectomy is also an effective procedure for gastrin suppression but debatable by some authors 1 .…”

Section: Discussionmentioning

confidence: 99%

Neuroendocrine neoplasms of the stomach

Louthan¹

2014

BIOMED PAP

View full text Add to dashboard Cite

Background. Gastric neuroendocrine neoplasms of type 1 and type 3 are different entities and as such require different therapeutical strategies. The aim of this study was to define and distinguish these two tumour subtypes with clearly different biological properties and patient survival. As shown, serum gastrin is an important diagnostic tool for differentiating the less malignant type 1 "hypergastrinemia non-related" tumor from malignant type 3, along with other parameters of malignant potential such as proliferation index and depth of invasion. Methods. The biological behaviour, tumour marker status, symptomatology, survival and therapeutical strategy were assessed and compared in 18 consecutive patients with type 1 and 7 with type 3 gastric neuroendocrine tumours. Results. All 18 patients with type 1 gastric carcinoids survived long-term. 17/18 patients were treated with endoscopic tumour removal. The prognosis for patients with generalized type 3 neuroendocrine neoplasms was poor, with shortterm survival. No statistically significant differences between the types were found in urine 5-hydroxyindolacetic acid concentration or serum chromogranin A concentration. Significant differences were found in serum gastrin with high levels even in localized type 1 tumors and normal levels in generalized type 3 neoplasm. Further, high neuron-specific enolase levels were found in type 3. Conclusions. Type 1 tumour should be preferably treated with endoscopic tumour removal. Recently, favourable tumoristatic effects have been reported in somatostatin analogs. Surgery is a treatment option for type 3 neuroendocrine carcinoma with normal gastrinemia. Serum gastrin is suitable for assessment of the biological properties of both neuroendocrine neoplasm types. It serves, among other factors, as a predictor of prognosis and an indicator for the selection of optimal therapeutical strategy.

show abstract

Treatment of ECL cell carcinoids with octreotide LAR

Abstract: During treatment the patients were still markedly hypergastrinaemic, whereas the serum CgA showed normalization. A diminished tumour load and reduced ECL cell density were found, indicating an antiproliferative effect of octreotide directly on the ECL cells.

Cited by 69 publications

References 17 publications

Neuroendocrine tumor disease: an evolving landscape

Neuroendocrine tumor disease: an evolving landscape

Somatostatin analogs for gastric carcinoids: For many, but not all

Neuroendocrine neoplasms of the stomach

Contact Info

Product

Resources

About